Naloxone enhances angiotensin II-induced increase in serum luteinizing hormone concentrations in normal women.
The present study was carried out in order to establish whether the stimulatory effect of angiotensin II (ANG II) on serum concentration of LH in women is under control by endogenous opioid peptides. For this purpose, the effect of ANG II (infusion for 60 min of successively increasing doses of 4, 8 and 16 ng/kg/min; each dose for 20 min) on serum LH levels was evaluated during administration of saline or the opioid antagonist naloxone (4 mg in an i.v. bolus followed by 10 mg over 2 h) in 7 normal women in both follicular and luteal phase. In all subjects, tests with saline alone (control test) or naloxone alone were performed. No significant changes in LH levels were observed in any test performed in the follicular phase and in the control test performed in the luteal phase. In contrast, in the luteal phase, both ANG II and naloxone induced significant increments in LH levels (23% increase vs. baseline by ANG II and 54% by naloxone). When naloxone and ANG II were given together stimulated LH increase was greatly enhanced. The mean peak was 154% higher than baseline and was higher than the sum of the individual peaks produced by naloxone and ANG II alone. These findings suggest inhibition by endogenous opioids of the stimulating action of ANG II on LH secretion during the luteal phase.
Coiro
V
V
Department of Internal Medicine, University of Parma, Italy.
Cigarini
C
C
Volpi
R
R
Capretti
L
L
Bacchi-Modena
A
A
Chiodera
P
P
D000328:Adult; D000804:Angiotensin II / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D005498:Follicular Phase; D006801:Humans; D008183:Luteal Phase; D007986:Luteinizing Hormone / Q000097:blood* / Q000378:metabolism; D009270:Naloxone / Q000494:pharmacology*; D012016:Reference Values; D013997:Time Factors
D000804:Angiotensin II; D009270:Naloxone; D007986:Luteinizing Hormone